Tisento Therapeutics

Executive Summary

Tisento Therapeutics is a preclinical-stage biotechnology company pioneering RNA-based therapeutics for rare genetic diseases. Founded in 2021 and headquartered in Cambridge, MA, the company leverages advanced RNA targeting and delivery technologies to modulate gene expression, aiming to develop transformative treatments for patients with limited or no therapeutic options. Tisento has raised $81 million in funding to advance its pipeline, which focuses on addressing the underlying genetic causes of rare diseases through novel RNA modalities. The company's platform enables precise modulation of gene expression, offering potential advantages over traditional gene therapy approaches in terms of safety and reversibility. While still in the preclinical stage, Tisento's innovative approach and strong financial backing position it as a promising player in the rare disease space. The company's progress over the next year will be critical in demonstrating the viability of its technology and advancing lead candidates toward clinical development. Key upcoming milestones include the filing of Investigational New Drug (IND) applications and the release of preclinical proof-of-concept data, which will be pivotal in validating its platform and attracting potential partnerships or further financing.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program30% success
• Q2 2026Preclinical Proof-of-Concept Data for Lead Candidate60% success
• TBDPotential Partnership or Licensing Deal40% success